GlassScriptPhysician profile
James Gregoire
NPI 1639673676
$2,849.00
in general payments reported to CMS, 2019-2025
19 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 76% of Cornea and External Diseases Specialist providers received nationally (typical 2025 total: $477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $220 · 2022: $239 · 2023: $664 · 2024: $492 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,389.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $970.76 | 2021-2025 | Tryptyr, Ngenuity, Wavelight Refractive Suite |
| Tarsus Pharmaceuticals, INC. | $559.24 | 2024-2025 | Xdemvy |
| Abbvie INC. | $497.90 | 2023-2025 | |
| Lumenis Be INC | $143.50 | 2023 | M22 |
| Horizon Therapeutics Plc | $131.33 | 2022-2023 | Tepezza |
| Dompe US, INC. | $82.70 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $62.68 | 2024-2025 | Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $60.64 | 2023 | Cequa |
| Amgen INC. | $56.00 | 2024 | Tepezza |
| Rayner Intraocular Lenses Limited | $44.80 | 2022-2024 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Sight Sciences, INC. | $39.55 | 2024 | Omni Surgical System |
| Astellas Pharma US INC | $36.00 | 2025 | Izervay |
| Ani Pharmaceuticals, INC. | $35.45 | 2025 | Purified Cortrophin Gel |
| Thea Pharma INC. | $31.50 | 2025 | Iyuzeh |
| Novartis Pharmaceuticals Corporation | $30.90 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $27.32 | 2025 | Ryzumvi, Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.90 | 2021 | |
| Harrow Eye, LLC | $16.83 | 2024 | Natacyn, Vevye |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gregoire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.